The GUARDIAN Trial - Vasopressor Sub-Study
Condition(s) studied
Investigational drug(s) / intervention(s)
Routine Blood Pressure Management: Routine blood pressure control.
Tight Blood Pressure Management: Tight blood pressure control.
Phenylephrine: Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
Norepinephrine: Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
Study summary
This is a sub-study of the overall GUARDIAN trial (NCT04884802) in which some GUARDIAN trial participants will be additionally randomized to norepinephrine or phenylephrine infusion to maintain the designated target intraoperative mean arterial pressure.
Eligibility
Primary outcome measure(s)
- Number of Participants with a Composite of Major Perfusion-Related Complications — During the initial 30 days after major non-cardiac surgery
The primary outcome is a composite of major perfusion-related complications (myocardial injury, stroke, non-fatal cardiac arrest, Stage 2-3 acute kidney injury, deep or organ-space infection, sepsis, and death) in the 30 days after major non-cardiac surgery.
Trial sites (11)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Nebraska Medical Center | Omaha | Nebraska | |
| MetroHealth Medical Center | Cleveland | Ohio | |
| Cleveland Clinic Fairview Hospital | Cleveland | Ohio | |
| Cleveland Clinic Main Campus | Cleveland | Ohio | |
| Beijing Shijitan Hospital, Capital Medical University | Beijing | China | |
| Peking Union Medical College Hospital | Beijing | China | |
| Shanghai Ninth People's Hospital | Shanghai | China | |
| Shanghai Chest Hospital | Shanghai | China | |
| West China Hospital | Sichuan | China | |
| University of Thessaly | Larissa | Greece | |
| National Defense College | Tokyo | Japan |
More The University of Texas Health Science Center, Houston trials in Japan
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04934748 on ClinicalTrials.gov ↗ ← All trials in Japan